The chairman of the board of directors of BerGenBio ASA ("BergenBio"), Sveinung Hole, has received proxies to vote at BerGenBio's Annual General Meeting to be held on 19 March 2021 for a total of 7,570,836 shares, representing approx. 8.62% of the total share capital in BerGenBio ASA.  

The proxies received are valid only for the Annual General Meeting to be held on 19 March 2021 and will automatically lapse thereafter. 

- END - 

About BerGenBio ASA  

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme focused on combination and single agent therapy in cancer, leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is developing a companion diagnostic test to identify patient populations most likely to benefit from  AXL inhibition: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy.   

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com  

Contacts 

ir@bergenbio.com

Richard Godfrey, CEO, BerGenBio ASA 

Rune Skeie, CFO, BerGenBio ASA 
rune.skeie@bergenbio.com 
+47 917 86 513 

This information is subject to disclosure pursuant to section 4-2 of the Norwegian Securities Trading Act.